Teva price target raised to $20 from $17 at Barclays

Barclays raised the firm’s price target on Teva to $20 from $17 and keeps an Overweight rating on the shares post the Q1 report. The analyst says Teva’s turnaround continues with compelling growth across Austedo, Ajovy and generics. The firm believes the company is in the “early innings of a long growth phase.”